What DIR reporting captures
Direct and indirect remuneration, or DIR, covers price concessions and adjustments that move among pharmacies, pharmacy benefit managers, and Medicare Part D plan sponsors after a prescription is dispensed. These amounts can change the actual cost of a drug, which is why plans must report them under Medicare Part D prescription drug coverage.
Regulators have revised the reporting format several times through CMS documents in the Federal Register to capture categories that earlier versions did not record clearly. Each revision adds fields or separates information that earlier submissions placed together. New columns can distinguish manufacturer rebates from pharmacy-level adjustments. They can also provide more detail about concessions that affect the final economics of a prescription.
The transaction can change after dispensing. A pharmacy may dispense a drug under one set of economic terms and learn months later that a retroactive fee or another adjustment reduced its effective reimbursement. The initial price or reimbursement amount may therefore differ from the amount that ultimately changes hands.
DIR reporting allows plans and regulators to compare those amounts. More detailed records cannot make every transaction easy to interpret, but they can show which concessions occurred and how those concessions changed the economics after dispensing.
Why the format keeps changing
Pharmacies have repeatedly raised concerns about retroactive fees. At the time a prescription is dispensed, a pharmacy may know the apparent economics of the transaction without knowing the full effect of a later adjustment. When a report combines several types of concessions in one category, it becomes harder to determine what changed the reimbursement.
Additional fields preserve distinctions that an earlier submission may have lost. A revised format can record a manufacturer rebate separately from an adjustment applied at the pharmacy level. It can also provide details about a particular concession instead of placing that amount with unrelated categories.
The transaction structure creates the need for this detail. Price concessions and adjustments can move among pharmacies, pharmacy benefit managers, and Part D plan sponsors at different stages of the process. A single visible price may not account for later changes that determine the final amount.
Regulators use reporting to examine what happens before deciding whether to place limits on these arrangements, as reflected in proposed Medicare Advantage and Part D regulations for CY 2019. The added columns provide a clearer record of the transaction. Their purpose is greater visibility into the amounts and timing, rather than a longer submission for its own sake.
What changes for plans and pharmacies
Format revisions affect the information plans submit and the systems used to submit it. Submission systems require front-end changes to match the updated reporting requirements. Plan and pharmacy staff must therefore handle new data fields along with revised validation rules.
The work may occur on a compressed schedule. Organizations must account for the new fields while adapting to the updated submission process. They also must preserve the distinctions that the revised format is meant to record. Continuing to use categories that combine different concessions can defeat that purpose.
For plans, more detailed reporting creates a fuller record of the amounts that affect the cost of drugs covered through Part D. For pharmacies, the revisions draw attention to adjustments that may not be visible when a prescription is dispensed. The initial reimbursement figure may fail to describe the final economics when later concessions change the amount.
The process also makes the timing of an adjustment easier to review. A record that identifies the concession type and includes additional detail can show whether the effective reimbursement changed after dispensing. Plans and regulators can use that information to evaluate the arrangement with a clearer account of what occurred.
What buyers can learn from the final price
For a buyer, an advertised drug price and the amount that ultimately changes hands may be different figures. The difference can arise from transaction details that most people do not see. A price shown at one point in the distribution chain may not reflect the complete economics of the transaction.
This does not mean that every buyer directly receives or pays a DIR adjustment. It means that the visible price may exclude later concessions or adjustments among the parties involved in dispensing and reimbursing the drug. The reporting process is intended to make those amounts and changes easier to see.
Cash GLP-1 pricing has its own version of this issue. Membership fees and dose changes can affect the total amount paid; our guide to actual GLP-1 costs works from paid amounts.
More detailed reporting cannot settle every dispute about reimbursement or concessions. It can give plans and regulators a clearer record of what happened after dispensing. That record supports review of retroactive fees and helps show whether the reported amounts match the economics that resulted.